Healthcare U.S. Community

The Hook: A Massive Valuation Disconnect While the market has pinned NexGel (NXGL) to its 52-week lows near $0.58 , the underlying business has just undergone a fundamental "rebirth." According to Simply Wall St’s intrinsic value model, the stock is currently 86.5% undervalued , with a fair value estimate of $4.30. This creates a rare setup where the market cap ($5M) is significantly lower than the company's projected annual revenue.Read more

In a nutshell: Hims & Hers has invested heavily and benefits are starting to show through growth and expansion. Investing continues with steps taken with a clear long term goal on the background, to be a front door for customers, the delivery channel, the platform and ecosystem.Read more

$BLCO & $COO. The Silence After the AGM: A Retail Investor’s Timeline, Findings, and Opinion on an Unprecedented Governance Failure By a Retail Investor and Portfolio Manager (Opinion) --- I.Read more

Lucid Diagnostics' EsoGuard is a novel screening tool for esophageal cancer. It is relatively non-invasive and may become widely accepted soon.Read more

I have followed ISRG since 2003 when it was brought to the investing club I had just joined. I tried to analyze ISRG with the BetterInvesting SSG methodology that I had been introduced to and I could not get it in the buy zone.Read more

RxSight (NASDAQ: RXST), maker of the only cataract lens that can be adjusted post-surgery, could be undervalued by an eye-popping margin More than 70% of RxSight Light Adjustable Lens (LAL) patients reported 20/20 or better vision after receiving the lens. Only 36.3% of non-adjustable lens patients reported the same.Read more

COMPANY ANALYSIS : Hims & Hers is a telehealth company founded in 2017 with the mission of improving wellness through accessible healthcare. The company operates primarily in the United States, Canada and Europe growing largely through the acquisition of the telehealth platform ZAVA, planning on further international growth.Read more

UnitedHealth (UNH): A Data Giant Hidden in an Insurer's Crisis Investment Narrative – February 2026 Price Target (12m): $395.00 (+35% upside) Rating: Strong Buy (Contrarian) 1. The Core Thesis: The "Optum" Mispricing The market is currently valuing UnitedHealth through the narrow lens of a traditional insurer struggling with Medicare Advantage (MA) rate cuts and CMS regulatory headwinds for 2027.Read more

The immediate impact of the Penumbra acquisition has been somewhat heavy on the stock’s valuation for a few key reasons: * Earnings Dilution: The acquisition is expected to be dilutive to adjusted earnings per share (EPS) by approximately $0.06 to $0.08 in the first full year. Investors often react to this "EPS drag" by pulling back, which we've seen in the recent price dips.Read more